Elevated fat levels in your liver can raise your chances of developing serious health issues, including diabetes, ...

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

Most of the rest of this information is about hepatocellular carcinoma and will be referred to as liver cancer. About 10% to 20% of liver cancers start in ... Chemotherapy and radiation therapy might ...

Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on ...

Researchers assessed the prognostic significance of older age and comorbidity burden on overall survival in patients with hepatocellular carcinoma.

Once cirrhosis is established, there is an annual risk for hepatocellular carcinoma of 1–2%. Environmental factors such as drinking patterns, coexisting liver disease, obesity, diet composition and ...

Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solution ...

Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCCAmezalpat builds momentum with both ...

Previously-untreated patients with hepatocellular carcinoma (HCC), a common form of liver cancer ... “live longer and have longer before their disease progresses than people who have sorafenib ...

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.

A cancer expert has shared the five types of cancer which are considered the most "lethal", and claimed people diagnosed with ...